Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S C Li

Showing results (341-350 of 368) with videos related to

Pageof 37
Sort By:
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|February 24, 2021
[HIV self-testing reagent use in pre-exposure prophylaxis and related factors in men who have sex with men]X Jin, H Y Wang, J Zhang, et al.
Cell|March 5, 2013
Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fateGreg M Findlay, Matthew J Smith, Fredrik Lanner, et al.
JAMA Oncology|December 29, 2022
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung CancerKirsty W C Lee, Molly S C Li, Wanxia Gai, et al.
Biophysical Journal|October 7, 2004
Imaging cells and tissues with refractive index radiologyY Hwu, W L Tsai, H M Chang, et al.
Clinical Lung Cancer|February 11, 2025
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib ProgressionWesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, et al.
Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.
JTO Clinical and Research Reports|April 9, 2024
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung DiseaseMolly S C Li, Kirsty W C Lee, Kevin K S Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|January 12, 2025
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancerStephanie P L Saw, Wen-Zhao Zhong, Rui Fu, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2024
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLCStephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Pageof 37

Showing results (341-350 of 368) with videos related to

Sort By:
Pageof 37
Zhonghua Liu Xing Bing Xue Za Zhi = Zhonghua Liuxingbingxue Zazhi|February 24, 2021
[HIV self-testing reagent use in pre-exposure prophylaxis and related factors in men who have sex with men]X Jin, H Y Wang, J Zhang, et al.
Cell|March 5, 2013
Interaction domains of Sos1/Grb2 are finely tuned for cooperative control of embryonic stem cell fateGreg M Findlay, Matthew J Smith, Fredrik Lanner, et al.
JAMA Oncology|December 29, 2022
Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung CancerKirsty W C Lee, Molly S C Li, Wanxia Gai, et al.
Biophysical Journal|October 7, 2004
Imaging cells and tissues with refractive index radiologyY Hwu, W L Tsai, H M Chang, et al.
Clinical Lung Cancer|February 11, 2025
CNS Outcomes of Osimertinib Plus Chemotherapy in Patients With EGFR Mutation Positive Lung Cancer Beyond Osimertinib ProgressionWesley K Y Wong, Kevin K S Mok, Giselle P C Tsui, et al.
Lung Cancer (Amsterdam, Netherlands)|November 4, 2025
Pattern of failure, impact of local therapy, and characteristics of long-term responders with advanced EGFR mutation positive non-small cell lung cancer treated with first-line osimertinibAllen C C Chen, Florence S T Mok, Wesley K Y Wong, et al.
JTO Clinical and Research Reports|April 9, 2024
Brief Report: Risk of Recurrent Interstitial Lung Disease From Osimertinib Versus Erlotinib Rechallenge After Symptomatic Osimertinib-Induced Interstitial Lung DiseaseMolly S C Li, Kirsty W C Lee, Kevin K S Mok, et al.
Lung Cancer (Amsterdam, Netherlands)|January 12, 2025
Asian Thoracic Oncology Research Group expert consensus statement on the peri-operative management of non-small cell lung cancerStephanie P L Saw, Wen-Zhao Zhong, Rui Fu, et al.
Lung Cancer (Amsterdam, Netherlands)|June 18, 2024
Real-world outcomes of pemetrexed-platinum chemotherapy plus osimertinib after progression on first-line osimertinib in advanced EGFR-mutated NSCLCStephanie P L Saw, Yi Fen Low, Gillianne G Y Lai, et al.
Cancer Treatment Reviews|June 1, 2026
PD-(L)1 containing rechallenge strategies in patients with advanced NSCLC previously treated with immunotherapy: A systematic review and meta-analysis across resistance phenotypesDaniele Marinelli, Fabrizio Citarella, Andrea Torchia, et al.
Pageof 37